XPH250117C51000
- 0.00
- 0.000.00%
Spdr Series Trust Spdr S&P Pharmaceuticals Etf Newsroom
U.S. Companies With Potential Pension Risk Transfer Restructuring Opportunities
Bulls Vs. Bears: Is the Schwab U.S. Dividend Equity ETF a Good Investment?
Don't Buy Weight-Loss Medication From Unauthorized Sources, UK Health Agency Warns About Risks
Smart Money Is Betting Big In JNJ Options
Weight Loss Drugs Can Cut Grocery Spending by up to 9%: Study
UK Approves Merck's Hypertension Drug Acquired Via $11 Billion Acceleron Pharma Deal
Pfizer, Atavistik to Collaborate on Allosteric Drug Discovery
US Employer Health Costs To Rise In 2025 Fueled By Weight Loss: Report
The three major US stock index futures rose collectively, and all seven giants were up in pre-market trading | Highlights for tonight.
① NVIDIA GB300 may be released in the second quarter of 2025; ② Eli Lilly and Co's weight loss drug tirzepatide has officially launched in China; ③ Apple announces price reductions.
Atavistik Bio Has Entered Into A Research Collaboration With Pfizer For Precision Allosteric Therapeutics, Leveraging Atavistik Bio's Platform To Identify And Validate Allosteric Binders Against Two Undisclosed, Pfizer-designated Targets, Financial...
$100 Invested In Eli Lilly 15 Years Ago Would Be Worth This Much Today
EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In December 2024 — Where Do Tesla, Nvidia, Quantum Computing Stock Rank?
Brand Prescription Drugs to Rise an Average 4.5% in 2025
How Is The Market Feeling About Pfizer?
Decoding Bristol-Myers Squibb's Options Activity: What's the Big Picture?
Dogs Of The Dow: Top 10 High-Yield Stocks Offering Dividends Up To 6.8% In 2025
Peering Into Bristol-Myers Squibb's Recent Short Interest
Eli Lilly Unusual Options Activity
Sangamo Therapeutics Stock Plunges As Pfizer Terminates Hemophilia Gene Therapy Pact
Takeda-backed Ascentage Pharma Files for $100M IPO